Why the study?
While the cardiotoxicity of trastuzumab is well established, the cardiotoxic effect of pertuzumab in HER2-positive cancer remains less well documented.
Does pertuzumab increase the risk of clinical heart failure or left ventricular systolic dysfunction in patients with HER2-positive cancer?
Does pertuzumab increase the risk of clinical heart failure or left ventricular systolic dysfunction in patients with HER2-positive cancer?
The addition of pertuzumab to standard HER2-directed therapy and chemotherapy significantly increases the risk of clinical heart failure in patients with HER2-positive cancer.
No takes yet. Share an insight, caveat, or question.
Pertuzumab increases clinical heart failure risk, warranting monitoring; confirms cardiotoxicity of dual HER2 blockade.
Alhussein et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: